Purpose

This is a Phase 1/2A study designed to evaluate the safety and tolerability of increased repeated doses of LYC-55716 in subjects with locally advanced or metastatic solid tumors.

Category

IRB Number
20170647HU
NCT Number
-
Open to Enrollment
Yes
Sponsor
Lycera Corp. -



Study Contact

Principal Investigator
Joseph Mccormick

Regulatory Point of Contact
Juliana Lopez
9565886655
lopezj21@uthscsa.edu



Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

    Exclusion Criteria


      Study Design

      Arm Groups